Sergei O. Bachurin
Russian Academy of Sciences
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Sergei O. Bachurin.
Experimental Gerontology | 2012
Ewa Malatynska; Harry W.M. Steinbusch; Olga Redkozubova; Alexei Bolkunov; Aslan Kubatiev; Naira Yeritsyan; Julie Vignisse; Sergei O. Bachurin; Tatyana Strekalova
The prevalence of depression increases with aging. We hypothesized that like humans, old animals exhibit anhedonic-like behavior, along with signs of behavioral despair. In rodents, anhedonia, a reduced sensitivity to reward, which is listed as a core feature of major depression in the DSM-IVR, can be measured by a decrease in intake of and preference for sweet solutions. Here, sucrose intake, forced swimming, immobility in the modified tail suspension test, novelty exploration, grooming, anxiety and locomotor activity were compared in naïve 3- and 18-month-old male C57BL/6 mice. The absolute amounts and the ratio of consumed 1% sucrose solution to water intake was significantly smaller in 18-month-old mice than in 3-month-old mice. The consumption of 5%-sucrose solution requiring high levels of drinking effort, novelty exploration in two setups and grooming behavior in the splash test were reduced in older animals. Analysis of other behaviors suggested that the above-mentioned signs of anhedonic-like traits were unlikely to be attributable to the potential effect of aging on metabolic needs for water, taste perception, motor capabilities or the induction of essential anxiety and neophobia. A 4-week treatment with the antidepressant imipramine (7mg/kg/day) or dimebon, a compound with suggested neuroprotective proneurogenic properties (1mg/kg/day) restored sucrose intake and preference in 18-month-old mice. Meanwhile, young and old mice showed no differences in the parameters of behavioral despair evaluated in the forced swim and modified tail suspension tests. Thus, the behavioral profile of aged mice parallels that of humans with elderly depression, in whom the symptoms of hedonic deficits typically outweigh affective disturbances. The assessment of anhedonic-like traits with the sucrose preference test in 18-month-old mice will be useful in preclinical studies of elderly depression.
Progress in Neuro-psychopharmacology & Biological Psychiatry | 2011
Julie Vignisse; Harry W.M. Steinbusch; Alexei Bolkunov; Joao Nunes; Ana Isabel Santos; Christian Grandfils; Sergei O. Bachurin; Tatyana Strekalova
Pre-clinical and clinical studies on dimebon (dimebolin or latrepirdine) have demonstrated its use as a cognitive enhancer. Here, we show that dimebon administered to 3-month-old C57BL6N mice 15 min prior to training in both appetitive and inhibitory learning tasks via repeated (0.1 mg/kg) and acute (0.5 mg/kg) i.p. injections, respectively, increases memory scores. Acute treatment with dimebon was found to enhance inhibitory learning, as also shown in the step-down avoidance paradigm in 7-month-old mice. Bolus administration of dimebon did not affect the animals locomotion, exploration or anxiety-like behaviour, with the exception of exploratory behaviour in older mice in the novel cage test. In a model of appetitive learning, a spatial version of the Y-maze, dimebon increased the rate of correct choices and decreased the latency of accessing a water reward after water deprivation, and increased the duration of drinking behaviour during training/testing procedures. Repeated treatment with dimebon did not alter the behaviours in other tests or water consumption. Acute treatment of water-deprived and non-water-deprived mice with dimebon also did not affect their water intake. Our data suggest that dimebon enhances hippocampus-dependent learning in both appetitive and inhibitory tasks in mice.
Behavior Research Methods Instruments & Computers | 2001
Tatyana V. Mukhina; Sergei O. Bachurin; N. N. Lermontova; Nikolai S. Zefirov
A crucial step in the estimation of properties of compounds in behavioral experiments is the quantification and description of the different effects observed. The goal of the present work was the automation of the Morris water maze test, one of the most popular behavioral methods for the study of animal memory. An original system was developed that provides fast and accurate tracking of animals, storage of the results in the database and video archive and a means of analyzing the results. This computerized version of the Morris water maze test permits the quantification of such vague characteristics of cognitive function as the “directionality” of search of the hidden platform after a standard training series. The suggestedparameters made it possible to discriminate cognitive properties of the novel compounds from other behavioral effects affecting escape latency. The effectiveness of this system was demonstrated in two experiments with neurochemically lesioned and drug-treated rats.
Molecular and Chemical Neuropathology | 1998
N. N. Lermontova; Nikolai Lukoyanov; Tatyana Serkova; Elena Lukoyanova; Sergei O. Bachurin
Effects of tacrine (1,2,3,4-tetrahydro-9-aminocridine) on memory deficits in rats treated with ethylcholine aziridinium ion (AF64A) were studied using active avoidance test in the two-way shuttle box. Neurotoxin AF64A injected at a dose of 6 nmol (i.c.v., bilaterally) causes nonspecific tissue damage in hippocampal fields CA2 and CA3. Two weeks after treatment with 6 nmol, AF64A active avoidance performance of toxin-treated rats was significantly deteriorated compared to vehicle-treated animals estimated in learning test (68 +/- 3.5 and 83 +/- 3.2% of correct responses, respectively; p < 0.01) and in retention test (53 +/- 5 and 76 +/- 3.6%, respectively; p < 0.01). Under these conditions, chronic treatment with tacrine at a daily dose of 1 mg/kg for 12-14 d reverses the effect of AF64A on the active avoidance performance both in learning (78 +/- 3.2%) and retention (72 +/- 4%) tests. It is supposed that behavioral effects of tacrine considerably depend on a severity of neurodegeneration in the hippocampus.
Cns & Neurological Disorders-drug Targets | 2017
Margarita E. Neganova; Sergei G. Klochkov; L. N. Petrova; E. F. Shevtsova; Svetlana Vasilievna Afanasieva; Ekaterina S. Chudinova; Vladimir P. Fisenko; Sergei O. Bachurin; George E. Barreto; Gjumrakch Aliev
BACKGROUNDnOxidative stress and amyloid deposition are tightly interconnected pathological features of Alzheimer disease. In this respect, both amyloid production and aggregation may be stimulated by oxidative stress and also the increase of pathogenic β-amyloid and its aggregated form lead to oxidative stress progression. Therefore, the search for potential drugs with both antioxidant and antiaggregation properties are of great interest.nnnMETHODSnIn this study, we described the stereospecific synthesis of alkaloid securinine aminoderivatives.nnnRESULTSnWe showed that the newly synthesized compounds possess antioxidant and metal-chelating properties. Indeed, we report that one compound has inhibitory effects towards μ-amyloid aggregation.nnnCONCLUSIONnBased on these results, aminoderivatives of securinine scaffold are promising compounds for development of new drugs for the treatment of neurodegenerative diseases.
Archive | 1996
Nikolai S. Zefirov; Andrei Zakharovich Afanasiev; Svetlana Vasilievna Afanasieva; Sergei O. Bachurin; Sergei Evgenievich Tkachenko; Vladimir Viktorovich Grigoriev; Marina Abramovna Jurovskaya; Valery Pavlovich Chetverikov; Elizaveta Evgenievna Bukatina; Irina Vladimirovna Grigorieva
Archive | 2006
Nikolai S. Zefirov; Andrei Zakharovich Afanasiev; Svetlana Vasilievna Afanasieva; Sergei O. Bachurin; Sergei Evgenievich Tkachenko; Vladimir Viktorovich Grigoriev; Marina Abramovna Jurovskaya; Valery Pavlovich Chetverikov; Elizaveta Evgenievna Bukatina; Irina Vladimirovna Grigorieva
Archive | 2007
Sergei O. Bachurin; Vladimir Viktorovich Grigoriev; Margarita Alekseevna Morozova; Allan Gerovich Beniashvili
Archive | 1996
Andrei Zakharovich Afanasiev; Svetlana Vasilievna Afanasieva; Sergei O. Bachurin; Elizaveta Evgenievna Bukatina; Valery Pavlovich Chetverikov; Vladimir Viktorovich Grigoriev; Irina Vladimirovna Grigorieva; Marina Abramovna Jurovskaya; Sergei Evgenievich Tkachenko; Nikolai S. Zefirov
Central nervous system agents in medicinal chemistry | 2015
Arturo Solis-Herrera; Ghulam Md Ashraf; María del Carmen Arias Esparza; Ruth Isabel Solís Arias; Sergei O. Bachurin; George E. Barreto; Gjumrakch Aliev